News

• Sanofi to evaluate the safety and efficacy of novel investigational candidate THOR-707 and KEYTRUDA® (pembrolizumab) in pursuit of establishing a new treatment option in oncology
  07:00 - GlobeNewswire
•  
• Merck revenue rises 1% YoY to $12.6B in Q3
  10/27/2020 / 11:56 - TeleTrader
•  
• Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
  09/17/2020 / 14:00 - GlobeNewswire
•  
• PTA-News: 4SC AG: 4SC expands avelumab supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer<BR/>for further clinical combination study of domatinostat in Merkel cell carcinoma
  09/15/2020 / 07:30 - pressetext
•  
• NKMax America Announces a Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer
  09/09/2020 / 01:00 - GlobeNewswire
•  
• Cocrystal Pharma Reports Second Quarter 2020 Financial Results and Provides Updates on Antiviral Programs
  08/06/2020 / 14:05 - GlobeNewswire
•  
• Merck EPS rise by 15% to $1.18 in Q2
  07/31/2020 / 12:51 - TeleTrader
•  
• Amid Global Pandemic, Launch of Smart Safety Syringe to Maximize Availability of Life-Saving Medicine
  07/06/2020 / 17:10 - GlobeNewswire
•  
• Vaccinex, Inc. to Present at the Virtual Investor Fireside Chat Series
  06/09/2020 / 14:00 - GlobeNewswire
•  
• COVID-19 vaccine time target 'very aggressive' - Merck CEO
  05/26/2020 / 17:43 - TeleTrader
•  
• Merck to work with IAVI on coronavirus vaccine
  05/26/2020 / 13:29 - TeleTrader
•  
• Surface Oncology and Merck to Collaborate on Immuno-Oncology Study Evaluating SRF617, Targeting CD39 in Combination with KEYTRUDA® (pembrolizumab) in Solid Tumor Patients
  05/20/2020 / 13:05 - GlobeNewswire
•  
• Vaccinex to Present Updated Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer at the American Society of Clinical Oncology (ASCO) 2020 Annual Meeting
  05/13/2020 / 23:02 - GlobeNewswire
•  
• Merck & Co's EPS climbs 13% to $1.26 in Q1
  04/28/2020 / 12:47 - TeleTrader
•  
• Updated Interim Results from CLASSICAL-Lung, Phase 1b/2 Study of Pepinemab (VX15/2503) in Combination with Avelumab (BAVENCIO®) in Non-Small Cell Lung Cancer Presented at the American Association for Cancer Research (AACR) Virtual Annual Meeting
  04/27/2020 / 13:45 - GlobeNewswire